|
OSI-7836
|
DB05837 |
[OSI-7836 is a member of the nucleoside class of cytotoxic drugs of which gemcitabine is the market leader. OSI Pharmaceuticals develops OSI-7836 as a next-generation gemcitabine. The anti-tumor activity of OSI-7836 appeares to be less schedule dependent than gemcitabine. It is also more active than ara-C (another clinically used nucleoside analog) in all nine models and more active than either paclitaxel or cisplatin in the two lung xenograft models tested. This drug shows no unexpected toxicities; those observed appeared to be similar to other nucleoside agents. ] |
|
8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
|
DB04505 |
|
|
Chlorophyll B
|
DB04506 |
[A light, silvery, metallic element. It has the atomic symbol Mg, atomic number 12, and atomic weight 24.31. Its salts are essential in nutrition, being required for the activity of many enzymes, especially those concerned with oxidative phosphorylation. It is a component of both intra- and extracellular fluids and is excreted in the urine and feces. Deficiency causes irritability of the nervous system with tetany, vasodilation, convulsions, tremors, depression, and psychotic behavior. (From Dorland, 27th ed)] |
|
AG-702
|
DB05836 |
[AG-702 is a recombinant human heat shock protein also known as stress protein. It is also known as HSPs, which are a group of proteins that are induced when a cell undergoes various types of environmental stresses like heat, cold and oxygen deprivation. HSPs are present in all cells in all life forms from bacteria to mammals, and their structure and function are similar across these diverse life forms. This drug is developed by antigenics for the treatment of genital herpes infection and is under phase I of clinical trial.] |
|
NS-3728
|
DB05835 |
[NS3728 is an orally active chloride channel blocker for the treatment of cancer.] |
|
Sp-722
|
DB04503 |
|
|
(3s)-2,3,4,5-Tetrahydropyridin-3-Amine
|
DB04504 |
|
|
OC-1012
|
DB05834 |
[OC-1012 is a compound which has emerged as a promising therapeutic agent for the treatment and prevention of mucositis, a serious side effect of chemotherapy and head and neck radiation therapy.] |
|
Camphane
|
DB04501 |
|
|
WRR-204
|
DB04502 |
|
|
PPI-1019
|
DB05832 |
[Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.] |
|
ING-1
|
DB05831 |
[ING-1 is a high-affinity, human engineered trade mark monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels on most adenocarcinomas. It is an attractive target for immunotherapy.] |
|
Acedoben
|
DB04500 |
|
|
Trestolone
|
DB05830 |
[Trestolone (7α-methyl-19-nortestosterone) is a synthetic androgen developed by the Population Council as a potential candidate drug for use in hormonal male contraceptive methods. In males, regular administration of sufficient quantities of trestolone induces a state of temporary infertility.] |
|
CHF 4227
|
DB05882 |
[CHF 4227 is a new selective estrogen receptor modulator (SERM). The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis. Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used in postmenopausal therapy.] |
|
EHT 0202
|
DB05881 |
[EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.] |
|
FR233623
|
DB03220 |
|
|
beta-D-fructofuranose 1,6-bisphosphate
|
DB04551 |
|
|
MBT-0312
|
DB05880 |
[MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors. ] |
|
MK-0736
|
DB15209 |
[MK-0736 is under investigation in clinical trial NCT00679055 (A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)).] |
